Skip to content

Study · Non-randomized trial · n = 15 · 2019

4 results

Intranasal oxytocin fails to acutely improve glucose metabolism in obese men.

Brede S, Fehr S, Dalla-Man C, Cobelli C, Lehnert H, Hallschmid M, Klement J

Diabetes, obesity & metabolism3 Oct 2018Cited by 19 (Europe PMC)

PMID30203536 (opens in a new tab)DOI10.1111/dom.13527 (opens in a new tab)PepBankPUB-30203536
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In obese men with impaired insulin sensitivity, a single intranasal oxytocin dose did not blunt postprandial glucose excursions during an oral glucose tolerance test.

    In plain wordsIn obese men, one oxytocin spray dose did not lower the rise in blood sugar after a sugar drink.

    Peptide
    Oxytocin
    Outcome
    No significant changePostprandial glucose excursion
    Study

    n = 15

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    24 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    In contrast to the results in normal-weight subjects, oxytocin did not blunt postprandial glucose and insulin excursions in obese men, and moreover failed to enhance beta-cell responsivity and glucose tolerance.
    2 context sentences
    Summary · context
    In the present experiment, we investigated the acute glucoregulatory impact of oxytocin in obese men with impaired insulin sensitivity.
    Summary · context
    Fifteen obese healthy men with an average body mass index of 35 kg/m2 and an average body fat content of 33% received a single intranasal dose (24 IU) of oxytocin before undergoing an oral glucose tolerance test.
  2. 02HumanNon-randomized trialEfficacy outcome

    In obese men with impaired insulin sensitivity, a single intranasal oxytocin dose did not blunt postprandial insulin excursions.

    In plain wordsIn obese men, one oxytocin spray dose did not lower the rise in insulin after a sugar drink.

    Peptide
    Oxytocin
    Outcome
    No significant changePostprandial insulin excursion
    Study

    n = 15

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    24 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    In contrast to the results in normal-weight subjects, oxytocin did not blunt postprandial glucose and insulin excursions in obese men, and moreover failed to enhance beta-cell responsivity and glucose tolerance.
    2 context sentences
    Summary · context
    In the present experiment, we investigated the acute glucoregulatory impact of oxytocin in obese men with impaired insulin sensitivity.
    Summary · context
    Fifteen obese healthy men with an average body mass index of 35 kg/m2 and an average body fat content of 33% received a single intranasal dose (24 IU) of oxytocin before undergoing an oral glucose tolerance test.
  3. 03HumanNon-randomized trialEfficacy outcome

    In obese men with impaired insulin sensitivity, a single intranasal oxytocin dose did not enhance beta-cell responsivity.

    In plain wordsIn obese men, one oxytocin spray dose did not improve how well insulin-making cells respond to sugar.

    Peptide
    Oxytocin
    Outcome
    No significant changeBeta-cell responsivity
    Study

    n = 15

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    24 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    In contrast to the results in normal-weight subjects, oxytocin did not blunt postprandial glucose and insulin excursions in obese men, and moreover failed to enhance beta-cell responsivity and glucose tolerance.
    2 context sentences
    Summary · context
    In the present experiment, we investigated the acute glucoregulatory impact of oxytocin in obese men with impaired insulin sensitivity.
    Summary · context
    Fifteen obese healthy men with an average body mass index of 35 kg/m2 and an average body fat content of 33% received a single intranasal dose (24 IU) of oxytocin before undergoing an oral glucose tolerance test.
  4. 04HumanNon-randomized trialEfficacy outcome

    In obese men with impaired insulin sensitivity, a single intranasal oxytocin dose did not enhance glucose tolerance.

    In plain wordsIn obese men, one oxytocin spray dose did not improve glucose tolerance.

    Peptide
    Oxytocin
    Outcome
    No significant changeGlucose tolerance
    Study

    n = 15

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    24 IU · intranasal · single doseAs given in this study (human).

    Source sentences

    Summary
    In contrast to the results in normal-weight subjects, oxytocin did not blunt postprandial glucose and insulin excursions in obese men, and moreover failed to enhance beta-cell responsivity and glucose tolerance.
    2 context sentences
    Summary · context
    In the present experiment, we investigated the acute glucoregulatory impact of oxytocin in obese men with impaired insulin sensitivity.
    Summary · context
    Fifteen obese healthy men with an average body mass index of 35 kg/m2 and an average body fat content of 33% received a single intranasal dose (24 IU) of oxytocin before undergoing an oral glucose tolerance test.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.